Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 256Breast Neoplasms 172Neoplasms 166Colorectal Neoplasms 155Neoplasm Metastasis 126Melanoma 118Recurrence 117Prostatic Neoplasms 116Leukemia, Myeloid, Acute 115Pancreatic Neoplasms 113Ovarian Neoplasms 109Multiple Myeloma 104Lung Neoplasms 95Stomach Neoplasms 89Squamous Cell Carcinoma of Head and Neck 82Triple Negative Breast Neoplasms 81Glioblastoma 81Lymphoma 76Lymphoma, Non-Hodgkin 75Carcinoma, Renal Cell 65Lymphoma, Large B-Cell, Diffuse 64Precursor Cell Lymphoblastic Leukemia-Lymphoma 62Advanced Solid Tumor 59Endometrial Neoplasms 58Carcinoma, Hepatocellular 58Small Cell Lung Carcinoma 54Uterine Cervical Neoplasms 52Sarcoma 52Myelodysplastic Syndromes 51Advanced Solid Tumors 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Unresectable Locally Advanced or Metastatic Solid Tumors × 1 year × Clear all
NCT06974812 2026-01-29

IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1/2 Recruiting
250 enrolled
Other solid neoplasm

Unresectable Locally Advanced or Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡